What is Broken String Biosciences?
Broken String Biosciences is a UK-based genomics company dedicated to building a sophisticated technology platform aimed at accelerating the development of cell and gene therapies. The company operates at the intersection of advanced genomics and therapeutic innovation, positioning itself as a key player in the burgeoning field of precision medicine. Its platform is designed to address critical challenges in the development pipeline for novel treatments.
How much funding has Broken String Biosciences raised?
Broken String Biosciences has raised a total of $15M across 1 funding round:
Series A
$15M
Series A (2023): $15M with participation from Heran Partners, Mérieux Equity Partners, Illumina Ventures, and Tencent
Key Investors in Broken String Biosciences
Heran Partners
Heran Partners is a Belgium-based venture capital investor focused on creating transformative impacts in the healthcare and life sciences sectors. They invest in innovative companies and teams that demonstrate strong scientific and entrepreneurial capabilities, providing them with capital, expertise, and mentorship.
Mérieux Equity Partners
Mérieux Equity Partners is a prominent European private equity firm specializing in the healthcare sector, established in 2009. The firm invests in companies with significant growth potential and transformative health products or services through two platforms: Innovation and Buyout.
Illumina Ventures
Illumina Ventures is a leader in genomics and precision health investing, focused on building an ecosystem that translates investment into innovation to enhance human health. The company supports various portfolio companies that are advancing life science research, biopharmaceutical drug development, and gene editing technologies.
What's next for Broken String Biosciences?
The substantial enterprise-level funding and recent strategic investment signal a pivotal growth phase for Broken String Biosciences. This capital infusion is expected to fuel the expansion of its technology platform, enhance research and development initiatives, and potentially broaden its market reach. The company is poised to leverage this financial backing to solidify its position and drive forward the next generation of cell and gene therapies.
See full Broken String Biosciences company page
